PolyPid Files NDA for D-PLEX100 After 60% SSI Reduction in Phase 3 Trial
PYPD•PolyPid submitted its NDA for D-PLEX100 on June 1, 2026, after the SHIELD II Phase 3 trial showed a 60% infection risk reduction in 798 colorectal surgery patients. It holds Breakthrough, Fast Track and QIDP designations and trades below $100 million versus $780 million Phase 1 deals.
1. NDA Submission Completed
PolyPid submitted a complete NDA for D-PLEX100 on June 1, 2026, seeking FDA acceptance and a PDUFA decision in Q1 2027. The application benefited from a $4.3 million fee waiver granted in March and carries Breakthrough, Fast Track and QIDP designations.
2. SHIELD II Phase 3 Trial Success
In the 798-patient SHIELD II trial, D-PLEX100 achieved a 60% relative reduction in surgical site infections (p=0.0013) across colorectal surgeries, meeting all primary and key secondary endpoints. A follow-on analysis also showed reduced infection severity, which could shorten hospital stays and lower costs.
3. Strategic Valuation Comparison
Trading below a $100 million valuation, PolyPid’s asset contrasts with Eli Lilly’s $780 million Phase 1 SSI vaccine acquisition, highlighting a potential market re-rating opportunity. The disparity underscores how far more advanced candidates can attract premium valuations in surgical infection prevention.
4. Commercial and Reimbursement Outlook
With Centers for Medicare & Medicaid Services penalties tied to surgical site infections and a new 30-day complication accountability model, hospitals face stronger incentives for prophylactic therapies. PolyPid’s late-stage status and ongoing U.S. commercial partnership discussions position it for near-term deals.
